Cellares has raised $82 million to accelerate the development of its Cell Shuttle, a factory-in-a-box that allows for the automation of the process of creating highly individualized cell therapies.
Cellares Corporation, a US-based life sciences technology company, announced on May 5, 2021 that it has raised $82 million in a Series B round to accelerate the development of its Cell Shuttle, a factory-in-a-box that allows for the automation of the process of creating highly individualized cell therapies, including chimeric antigen receptor (CAR)-T therapies.
According to a company press release, the Cell Shuttle is equipped with hardware, software, robotics, and consumables, making it capable of producing 10 patient doses simultaneously, while allowing for easily transferable pre-clinical development and efficient commercial scalability.
“There are more than 450,000 patients today who could potentially benefit from CAR-T cell therapies, a number expected to grow into the millions in a few years’ time. Less than 1% of these patients are able to get access to these therapies, due to a lack of scalable cell manufacturing technologies,” said Fabian Gerlinghaus, co-founder and CEO of Cellares, in the press release.
Source: Cellares
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.